Publications by authors named "Mohammad Hasanzade"
Neurosurg Rev
September 2024
Article Synopsis
- Meningiomas are the most common brain tumors, and surgical removal is the primary treatment, but options become limited if that fails; this study explores the use of bevacizumab, an antibody that hinders blood vessel formation, as a potential treatment.
- A systematic review analyzed 12 studies involving 243 patients and 310 tumors, primarily retrospective, showing an average progression-free survival of about 19 months and overall survival of nearly 24 months with bevacizumab treatment.
- The research indicates that bevacizumab could be effective for difficult-to-treat meningiomas, particularly in patients with high-grade tumors or neurofibromatosis, while identifying factors like patient gender and previous treatments that may affect outcomes
